We scan new podcasts and send you the top 5 insights daily.
While prophylactic tocilizumab is standardly adopted to reduce CRS in multiple myeloma patients receiving BCMA-targeted bispecifics, it is unnecessary for CD20-targeted lymphoma bispecific antibodies. Due to differing tumor microenvironments and targets, CD20 bispecifics carry a distinct toxicity profile where routine tocilizumab prophylaxis provides no demonstrable clinical need, reserving the IL-6 inhibitor strictly for grade 2 or higher CRS.
Prophylactically administering tocilizumab before bispecific antibody treatment can slash the incidence of cytokine release syndrome (CRS) from ~75% down to 20%. This simple intervention, analogous to using G-CSF for neutropenia, mitigates side effects and makes outpatient administration a much safer and more feasible option for patients.
The LOTUS-7 trial (loncastuximab + glofitimab) illustrates a key principle for using bispecific antibodies safely: combining them with another active, tumor-debulking drug mitigates Cytokine Release Syndrome (CRS). The speaker identifies this as a "thematic" finding, where reducing tumor bulk directly lowers the risk of this major toxicity, making potent combinations more tolerable.
When utilizing the combination of polatuzumab vedotin and mosunetuzumab in aggressive lymphoma, sequencing matters. Giving polatuzumab vedotin first depletes circulating B cells prior to bispecific antibody exposure. Dr. Budde notes that debulking tumor burden and clearing circulating target cells in this manner significantly lowers the subsequent incidence and severity of cytokine release syndrome.
While prophylactic tocilizumab is used to mitigate CRS with bispecific antibodies in multiple myeloma, this practice should not be applied to lymphoma patients. Rates of high-grade CRS with CD20-bispecifics in lymphoma are low single digits, making routine prophylaxis unnecessary and exposing patients to a drug they likely don't need.
Administering tocilizumab before the first bispecific antibody dose significantly reduces Cytokine Release Syndrome (CRS) risk. This proactive strategy enables safer outpatient treatment, lowering hospital admissions and improving patient access, especially in community settings.
Giving tocilizumab prophylactically before bispecific antibody administration is a key strategy to mitigate Cytokine Release Syndrome. This practice, supported by NCCN guidelines and generally reimbursed, significantly reduces CRS risk, making it safer and more feasible to deliver these therapies in an outpatient setting.
To mitigate the risk of severe Cytokine Release Syndrome (CRS) from bispecific antibodies in patients with high tumor burden, a debulking strategy is effective. Administering two initial cycles of chemotherapy dramatically reduces disease volume, leading to almost zero CRS when the bispecific is introduced, making the treatment much safer.
The IntentiMig trial showed that proactively administering tocilizumab with a bispecific antibody resulted in a zero percent incidence of cytokine release syndrome (CRS). This safety improvement could be pivotal for the broader adoption of bispecifics in community oncology settings, which are less equipped to manage severe side effects.
Giving prophylactic tocilizumab before bispecific antibody administration is a highly effective strategy to mitigate Cytokine Release Syndrome (CRS). This approach can reduce CRS rates from ~70% to 5-14%, making outpatient step-up dosing a much more feasible and safer option for community oncology centers.
In heavily pretreated relapsed/refractory follicular lymphoma, it's crucial to perform a tumor biopsy to check for CD20 expression before choosing a CD20-targeting bispecific antibody. Prior treatments can lead to loss of the antigen, which would render the bispecific ineffective.